All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, August 15, 2022
Home » Blogs » BioWorld Perspectives » Extra! Extra! Leukemia Treatment Purposely Misses Holy Grail!

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Immunotherapy / Cancer / Medicare

Extra! Extra! Leukemia Treatment Purposely Misses Holy Grail!

Aug. 11, 2011
By Anette Breindl
No Comments

This week’s report of remissions in three advanced leukemia patients after immunotherapy has generated quite a lot of excitement in the media – which, in turn, has led to some backlash amongst the twitterati and in the blogosphere, noting that two complete remissions plus a partial one don’t make a blockbuster. Or anything, really, that will be broadly useful within the next few years. Mainly, when I look at these controversies, I am grateful that I write for such a smart audience. If you are reading this blog, chances are that you work in the biopharmaceutical industry – and if you do, there are exactly two possibilities: you know that most early stage treatments ultimately fail – or you’ve got bigger problems than whether my headlines are overly enthusiastic. Thank you, dear reader! And I’ll admit that I was rather amused to read in several headlines that cancer immunotherapy is now the “holy grail” of cancer targeting, and that this work advances us toward that holy grail. I distinctly remember from last year that eradicating stem cells is the holy grail of cancer therapy. And these CAR T cells target the surface marker they do, CD19, specifically because it is not on stem cells. Ergo, this can’t be the holy grail of cancer therapy. So there. Still, I’ll bet my own headline above made you do a double take. The fact of the matter is, few people want to read about the many things in science that don’t work. Few people want to read that this is an incremental advance, or the bigger story: three patients have had remissions, two died last year in separate trials using a similar approach, and we’ll know whether the approach works and is safe around, oh, 2016 if all goes well. Or maybe 2020. I don’t know what the right answer is in terms of reporting advances. I suppose having a holy grail of the year isn’t it. Still, I agree with my colleague Catherine Shaffer’s recent post about how science has ceded the language of hope and instead made itself comfortable in a culture of low expectations – and why that’s a problem. Yes, holy grail is over the top. So is some of the other coverage of this news. But is it really better to write “Early stage advance has an 8 percent chance of leading to cancer treatment decades hence?” And yes, it’s very important for anyone writing for a general audience, including cancer patients, to be explicit about the fact that these results will take a while to reach them, if they ever do. But the fact of the matter is, this is how the blockbusters, the game-changers, the lifesavers get their start: with two or three or five eye-popping successes that make drug developers take notice, and do what it takes to get to the next step. And yes, most of these starts are false ones. But all of the real starts start here. They do not start with the quacks and hacks who advocate maple syrup and baking soda, as Catherine detailed in her blog post, or breast milk, which a woman at my church swears cured a family member of leukemia and cheerfully recommends to anyone with a newly diagnosed relative, dismissing their anguish and fears in a way that is as grating as any oncologist demigod could be, in the name of “positive thinking.” It may be worth remembering a similar ruckus in 1998, when the New York Times ran a story about the promise of angiogenesis. EntreMed Inc. had a huge stock run-up, followed soon enough by a crash. The fur flew on the then smaller Internet, including a rather angry article titled “The New York Times Cures Cancer!” Whether the New York Times article was overly optimistic (for the record, I didn’t think so, but you can read the story yourself or its placement above the fold on p. 1 of the Sunday Times was too prominent is hard to say. But my point is this: blocking angiogenesis is now a successful clinical strategy. I’ll say it one more time: Most of these starts are false ones. But all of the real starts start here. We need to watch our language. But we can avoid reporting on the duds only at the price of not reporting on early signs of hope at all, leaving those looking for hope to search among the baking soda and the breast milk.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 15, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 15, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing